SCHEMBL874035

SCHEMBL874035

CC(=O)N(O)c1ccc(O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
MAPT P10636 4/20 0.41
CA12 O43570 4/20 0.41
CA1 P00915 4/20 0.41
CA2 P00918 4/20 0.41
CA9 Q16790 4/20 0.41
CA14 Q9ULX7 4/20 0.41
CA3 P07451 3/20 0.41
CA4 P22748 3/20 0.41
CA7 P43166 3/20 0.41
MEN1 O00255 2/20 0.41
CYP3A4 P08684 2/20 0.41
KMT2A Q03164 2/20 0.41
HSD17B1 P14061 1/20 0.41
BRD4 O60885 1/20 0.41
NR1I2 O75469 1/20 0.41
MB P02144 1/20 0.41
CYP1A1 P04798 1/20 0.41
RARG P13631 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3279618 0.81 RAB9A (0.53) ALDH1A1MEN1KMT2ATSHRKDM4E
SCHEMBL874506 0.79 MAPT (0.50) ALDH1A1MAPTMEN1KMT2AHSD17B1
SCHEMBL17671272 0.79 MEN1 (0.45) ALDH1A1MAPTCA1CA2MEN1
SCHEMBL17671283 0.79 TSHR (0.42) CA1CA2MEN1KMT2ATSHR
SCHEMBL17671282 0.79 TPMT (0.39) ALDH1A1MAPTCA1CA2KMT2A
SCHEMBL17671229 0.79 ALOX15 (0.50) ALDH1A1MAPTCA12CA1CA2
SCHEMBL7153902 0.78 ESR1 (0.47) ALDH1A1MAPTCA12CA1CA2
SCHEMBL440963 0.78 KDM4E (0.48) ALDH1A1MAPTMEN1CYP3A4KMT2A
SCHEMBL10292556 0.78 ALDH1A1 (0.45) ALDH1A1MAPTCA12CA1CA2
SCHEMBL30127710 0.78 ALDH1A1 (0.43) ALDH1A1MAPTCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4727818-B2 2011-07-20 JP claimed
EP-1128730-B1 ANTIMICROBIAL COMPOSITION COMPRISING AN OXIDOREDUCTASE AND AN ENHANCING AGENT OF THE N-HYDROXYANILIDE-TYPE NOVOZYMES AS (DK) 2003-05-02 EP claimed
JP-2002529380-A 2002-09-10 JP claimed
US-20020094331-A1 ANTIMICROBIAL COMPOSITION CONTAINING AN OXIDOREDUCTASE AND AN ENHANCER OF THER N-HYDROXYANILIDE-TYPE NOVOZYMES A/S (DK) 2002-07-18 US claimed
EP-1128730-A1 ANTIMICROBIAL COMPOSITION COMPRISING AN OXIDOREDUCTASE AND AN ENHANCING AGENT OF THE N-HYDROXYANILIDE-TYPE Novozymes A/S (DK) 2001-09-05 EP claimed
WO-2000027204-A1 ANTIMICROBIAL COMPOSITION COMPRISING AN OXIDOREDUCTASE AND AN ENHANCING AGENT OF THE N-HYDROXYANILIDE-TYPE NOVOZYMES A/S (DK) 2000-05-18 WO claimed
EP-0759171-B1 PARACETAMOL PHOSPHATE FOR IMMUNOASSAYS CAMBRIDGE LIFE SCIENCES (GB) 1998-04-15 EP claimed
EP-0759171-A1 PARACETAMOL PHOSPHATE FOR IMMUNOASSAYS CAMBRIDGE LIFE SCIENCES PLC (GB) 1997-02-26 EP claimed
WO-1995031724-A1 PARACETAMOL PHOSPHATE FOR IMMUNOASSAYS CAMBRIDGE LIFE SCIENCES PLC (GB) 1995-11-23 WO claimed
EP-4585211-A2 PULLULAN CAPSULES Capsugel Belgium NV (BE) 2025-07-16 EP disclosed
EP-3609476-B1 PULLULAN CAPSULES CAPSUGEL BELGIUM NV (BE) 2025-06-04 EP disclosed
EP-3167869-B1 TAMPERPROOF ORAL DOSAGE FORM CAPSUGEL BELGIUM NV (BE) 2025-02-12 EP disclosed
EP-3444336-B1 CLEANING AGENT PROCTER & GAMBLE (US) 2024-05-08 EP disclosed
US-11975107-B2 Compositions and resulting hard capsules comprising hydrophilic coloring foodstuff concentrates CAPSUGEL BELGIUM NV (BE) 2024-05-07 US disclosed
CN-1041695-A Medicine for veterinary and human medicine having antiviral and antitumor effects and method for preparing pharmaceutical form comprising the same BAREND WILLEM HAK (NL) 1990-05-02 CN disclosed
CN-88100516-A The method of delaying gelatification of water-solubility polymer 1988-09-07 CN disclosed
US-4520134-A ANALGESICS ROSEN GERALD M (US) 1985-05-28 US disclosed
EP-0116637-A4 N-ALKYL-4'-HYDROXYACETANILIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE. ROSEN GERALD M 1985-02-18 EP disclosed
EP-0116637-A1 N-ALKYL-4'-HYDROXYACETANILIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE ROSEN, Gerald M. (US) 1984-08-29 EP disclosed
WO-1984000886-A1 N-ALKYL-4'-HYDROXYACETANILIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE ROSEN GERALD M 1984-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020094331-A1 ANTIMICROBIAL COMPOSITION CONTAINING AN OXIDOREDUCTASE AND AN ENHANCER OF THER N-HYDROXYANILIDE-TYPE LPO, MPO, LCT ALDH1A1 406/4885MAPT 2768/4885CA12 2336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.